<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918148</url>
  </required_header>
  <id_info>
    <org_study_id>2193/2018</org_study_id>
    <nct_id>NCT03918148</nct_id>
  </id_info>
  <brief_title>Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)</brief_title>
  <acronym>GIOIA</acronym>
  <official_title>Effects of Gliflozins on Markers of Cardiovascular Risk in Type 2 Diabetes (GIOIA): a Multicenter Pragmatic Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GIOIA represents a multicenter pragmatic prospective cohort study, aimed at evaluating the
      effects of SGLT2 inhibitors currently marketed (dapagliflozin, canagliflozin, empagliflozin)
      on markers of vascular, myocardial and renal damage, in patients with type 2 diabetes not
      well controlled with metformin and/or basal insulin. The changes of the interest outcomes are
      compared with those obtained with a comparator glucose lowering class (DPP-4inhibitors) over
      a follow-up of two years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid intima-media thickness (CIMT)</measure>
    <time_frame>24 months</time_frame>
    <description>Progression (increase in mean CIMT in millimeters [mm]) or regression (reduction &gt; o = 0.020 mm on mean CIMT) after 2 years of follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial stiffness indexes</measure>
    <time_frame>24 months</time_frame>
    <description>Change from baseline in:
Left Ventricular Ejection Fraction (LVEF) in percentage (%), Diastolic Left Ventricular Dimension (LVDs) in centimeters (cm) Interventricular Septum thickness (IVS) in cm left vetricular posterior wall thickness (PWs) in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary albumin to creatinine ratio excretion</measure>
    <time_frame>24 months</time_frame>
    <description>Development of microalbuminuria in normoalbuminuric patients at baseline or development of macroalbuminuria in patients with microalbuminuria at baseline; regression of microalbuminuria to normoalbuminuria or regression of macroalbuminuria to microalbuminuria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>24 months</time_frame>
    <description>Change in body weight in kilograms (kg) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>24 months</time_frame>
    <description>Change in body mass index in Kg/mq from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference (WC)</measure>
    <time_frame>24 months</time_frame>
    <description>Change in waist circumference in cm from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 months</time_frame>
    <description>Change in systolic and dyastolic blood pressure in mmHg from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated Glomerular filtration rate (eGFR)</measure>
    <time_frame>24 months</time_frame>
    <description>Change in estimated glomerular filtration rate in mI/min/1.73 mq from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1c</measure>
    <time_frame>24 months</time_frame>
    <description>Change in HbA1c in % from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean amplitude glucose excursions (MAGE)</measure>
    <time_frame>24 months</time_frame>
    <description>Change in MAGE in mmol/L from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid profile</measure>
    <time_frame>24 months</time_frame>
    <description>Change in total cholesterol, tryglicerides, HDL-cholesterol, and LDL-cholesterol in mg/dL from baseline</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">555</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SGLT-2i</arm_group_label>
    <description>Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:
dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPP-4i</arm_group_label>
    <description>Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:
sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT-2i</intervention_name>
    <description>Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin</description>
    <arm_group_label>SGLT-2i</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4i</intervention_name>
    <description>Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin</description>
    <arm_group_label>DPP-4i</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women with type 2 diabetes attending diabetes centers of the Campanian county
        treated with metformin and/or basal insulin who start therapy with a SGLT-2i or DPP-4i
        according to the clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes for at least 5 years

          -  new use of an SGLT2-I or DPP4-I as add-on to metformin or insulin according to
             clinical practice

          -  HbA1c levels ≥ 7% and ≤ 8.5%

          -  eGFR ≥ 60 ml/min/1.73 m2

        Exclusion Criteria:

          -  Type 1 diabetes or secondary diabetes resulting from specific causes

          -  History of neurovascular ulcers

          -  Previous therapy with SGLT-2i or DPP4-i in the 3 months prior to the study enrollment

          -  History of cancer within the last 5 years

          -  Pregnancy or active breast-feeding

          -  Serum creatinine level ≥ 1.3 mg/dl in women and ≥ 1.4 mg/dl in men

          -  eGFR ≤ 60 ml/min/1.73 m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Esposito</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dario Giugliano</last_name>
    <role>Study Director</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Esposito</last_name>
    <phone>+39 0815665031</phone>
    <email>katherine.esposito@unicampania.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unit of Diabetes</name>
      <address>
        <city>Naples</city>
        <state>Campania</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Esposito</last_name>
      <phone>+39 0815665005</phone>
      <email>katherine.esposito@unicampania.it</email>
    </contact>
    <investigator>
      <last_name>Maria Ida Maiorino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michela Petrizzo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurizio Gicchino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miriam Longo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Bellastella</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Giugliano D, Maiorino MI, Longo M, Esposito K. Are gliflozins the new statins for diabetes? Diabetes Res Clin Pract. 2019 Jul;153:191-193. doi: 10.1016/j.diabres.2019.04.014. Epub 2019 Apr 5.</citation>
    <PMID>30959149</PMID>
  </reference>
  <reference>
    <citation>Giugliano D, Maiorino MI, Bellastella G, Esposito K. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine. 2018 Jul;61(1):23-27. doi: 10.1007/s12020-017-1517-9. Epub 2018 Jan 10. Review.</citation>
    <PMID>29322300</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>April 13, 2019</last_update_submitted>
  <last_update_submitted_qc>April 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Katherine Esposito</investigator_full_name>
    <investigator_title>Full Professor of Endocrinology and Metabolic Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

